Marie-Laure Keyrouz

Oct 3, 2024 | ionanalytics.com | Rupert Cocke |Marie-Laure Keyrouz |Lloyd Vassell

European construction deals could be put in the freezer if conflict in the Middle East heats up and keeps oil prices high for a sustained period. Brent crude jumped above USD 75 per barrel as Iran responded to Israeli attacks on its proxies in Lebanon and Yemen. Although both sides appear to be taking care to avoid a full-scale regional war, the risks of a miscalculation, on either side, could be catastrophic.

Aug 8, 2024 | ionanalytics.com | Ben Miller |Ben Watson |Marie-Laure Keyrouz |Lucinda Guthrie

Data Insight This report is a comprehensive overview of the European buyout market using best-in-class Leveraged Finance and M&A data across ION Analytics. To see the full report, please click below. Key Trends in 1H24:Buyouts totalled EUR 95bn, up 168%, led by Apollo’s EUR 10.1bn acquisition of a 49% stake in the joint venture entity related to Fab 34. Issuance of leveraged loans recovered in 2Q24, rising 62% from 1Q24 to EUR 8.13bn and totalling EUR 13.1bn for 1H24.

Aug 8, 2024 | ionanalytics.com | Avery Champion |Ben Watson |Marie-Laure Keyrouz |Lucinda Guthrie

Data Insight This report is a comprehensive overview of the US buyout market, using best-in-class Leveraged Finance and M&A data across ION Analytics. To see the full report, please click belowKey Trends in 1H24:Buyouts surged to USD 146bn in 1H24, from USD 108bn in 1H23, led by Truist Insurance’s USD 12.3bn acquisition by Stone Point Capital, Clayton Dubilier & Rice and Mubadala Investment.

May 13, 2024 | ionanalytics.com | Jonathan Smith |Samantha Shaji |Marie-Laure Keyrouz |Lloyd Vassell

Oncology is a growth area for the European biotech industry and experts see large pharmaceutical companies continuing to snap up new intellectual property (IP) over the coming few years. “Interest in oncology M&A is continuously growing as the top 20 pharma companies face the imminent loss of exclusivity of some of their best performing cancer drugs in the next five to six years,” said Fady Riad, CEO of the consulting firm Centurion Life Sciences.

Nov 23, 2023 | ionanalytics.com | Jonathan Smith |Santosh Shetty |Marie-Laure Keyrouz |Lucy Chapman

This is an overview of Mergermarket’s proprietary intelligence in the regenerative health space in Europe over the last five months, featuring existing opportunities in the market. Snapshot is the new name for a Preview.  Regenerative medicine – a broad term encompassing engineered tissues, as well as next-generation gene and cell therapies – is a growth area for the European biotech industry and experts expect dealmaking to increase as the innovations gain traction.